Gilead joins a lineup of Big Pharma partners betting big on TriNKETs, with a $300M cash ante to get started on a 5T4
Bill Haney’s Dragonfly Therapeutics is making the vault between biotech startup and the next big level: adding clinical-stage compounds to its own fledgling pipeline while welcoming another Big Pharma name to a lineup of industry partnerships that are now moving toward their own clinical destinies.
Uncharacteristic of the new generation of startups, Haney — who has steadfastly avoided the limelight of public company status, now turned into a harsh spotlight for many — just scored a major preclinical deal with Gilead that contributes $300 million to the cash reserves at Dragonfly.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.